Skip to content
2000
Volume 10, Issue 1
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704

Abstract

Dose limitations in therapy induced by adverse effects due to unselective drug availability are a common problem. One prominent example for this dilemma are inflammatory diseases of the gastrointestinal tract. The challenge for drug delivery systems in the therapy of these diseases is the delivery of the active ingredient to the site of inflammation. Colloidal carriers allow to improve delivery of drugs to the site of action and appear promising to overcome this general therapeutic drawback. Here we focus on nanocarrier-based drug delivery strategies for the treatment of common inflammatory disorders like inflammatory bowel disease and gastric ulcer.

Loading

Article metrics loading...

/content/journals/cdd/10.2174/1567201811310010004
2013-02-01
2025-05-01
Loading full text...

Full text loading...

/content/journals/cdd/10.2174/1567201811310010004
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test